Anders Sundan

Summary

Affiliation: Norwegian University of Science and Technology
Country: Norway

Publications

  1. doi Mn2+ regulates myeloma cell adhesion differently than the proadhesive cytokines HGF, IGF-1, and SDF-1alpha
    Tobias S Slørdahl
    Department of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology NTNU, Trondheim, Norway
    Eur J Haematol 81:437-47. 2008
  2. doi Hepatocyte growth factor promotes migration of human myeloma cells
    Randi Utne Holt
    Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, MTFS, N 7489 Trondheim, Norway
    Haematologica 93:619-22. 2008
  3. doi HGF and IGF-1 synergize with SDF-1α in promoting migration of myeloma cells by cooperative activation of p21-activated kinase
    Torstein Baade Rø
    KG Jebsen Center for Myeloma Research and Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway
    Exp Hematol 41:646-55. 2013
  4. pmc c-Met signaling promotes IL-6-induced myeloma cell proliferation
    Håkon Hov
    Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway
    Eur J Haematol 82:277-87. 2009
  5. pmc High expression of BCL3 in human myeloma cells is associated with increased proliferation and inferior prognosis
    Anne Tove Brenne
    Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway
    Eur J Haematol 82:354-63. 2009
  6. ncbi A selective c-met inhibitor blocks an autocrine hepatocyte growth factor growth loop in ANBL-6 cells and prevents migration and adhesion of myeloma cells
    Håkon Hov
    Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway
    Clin Cancer Res 10:6686-94. 2004
  7. doi Immunohistochemical analysis of hepatocyte growth factor and c-Met in plasma cell disease
    Karin F Wader
    Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway
    Histopathology 60:443-51. 2012
  8. ncbi Osteopontin is an adhesive factor for myeloma cells and is found in increased levels in plasma from patients with multiple myeloma
    Therese Standal
    Department of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway
    Haematologica 89:174-82. 2004
  9. doi Lymphoma and myeloma cells are highly sensitive to growth arrest and apoptosis induced by artesunate
    Toril Holien
    Department of Cancer Research and Molecular Medicine, KG Jebsen Center for Myeloma Research, Norwegian University of Science and Technology, Trondheim, Norway
    Eur J Haematol 91:339-46. 2013
  10. ncbi HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma
    Therese Standal
    Department of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway
    Blood 109:3024-30. 2007

Collaborators

Detail Information

Publications39

  1. doi Mn2+ regulates myeloma cell adhesion differently than the proadhesive cytokines HGF, IGF-1, and SDF-1alpha
    Tobias S Slørdahl
    Department of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology NTNU, Trondheim, Norway
    Eur J Haematol 81:437-47. 2008
    ..In conclusion, this study shows a potential important role of divalent cations in MM cell biology and supports earlier studies pointing to activated VLA-4 as a key for homing of MM cells to the BM...
  2. doi Hepatocyte growth factor promotes migration of human myeloma cells
    Randi Utne Holt
    Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, MTFS, N 7489 Trondheim, Norway
    Haematologica 93:619-22. 2008
    ..Hepatocyte growth factor-mediated migration was dependent on phosphatidylinositol-3-kinase, involved the MAPK/Erk signaling cascade and VLA-4 integrins, but did not involve Akt, mTOR or G proteins...
  3. doi HGF and IGF-1 synergize with SDF-1α in promoting migration of myeloma cells by cooperative activation of p21-activated kinase
    Torstein Baade Rø
    KG Jebsen Center for Myeloma Research and Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway
    Exp Hematol 41:646-55. 2013
    ..These findings are likely to be of clinical relevance because multiple myeloma cells are located in an environment containing HGF and IGF-1 and are exposed to an SDF-1α gradient between the bone marrow and peripheral blood. ..
  4. pmc c-Met signaling promotes IL-6-induced myeloma cell proliferation
    Håkon Hov
    Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway
    Eur J Haematol 82:277-87. 2009
    ..We therefore wanted to investigate if HGF could influence the effects of interleukin (IL)-6...
  5. pmc High expression of BCL3 in human myeloma cells is associated with increased proliferation and inferior prognosis
    Anne Tove Brenne
    Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway
    Eur J Haematol 82:354-63. 2009
    ..BCL3 is a putative oncogene encoding for a protein belonging to the inhibitory kappaB-family. We experienced that this putative oncogene was a common target gene for growth-promoting cytokines in myeloma cell lines...
  6. ncbi A selective c-met inhibitor blocks an autocrine hepatocyte growth factor growth loop in ANBL-6 cells and prevents migration and adhesion of myeloma cells
    Håkon Hov
    Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway
    Clin Cancer Res 10:6686-94. 2004
    ..We wanted to examine the role of the hepatocyte growth factor (HGF) receptor c-Met in multiple myeloma by applying a novel selective small molecule tyrosine kinase inhibitor, PHA-665752, directed against the receptor...
  7. doi Immunohistochemical analysis of hepatocyte growth factor and c-Met in plasma cell disease
    Karin F Wader
    Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway
    Histopathology 60:443-51. 2012
    ..Our aims were to investigate whether HGF and c-Met are present in bone marrow and extramedullary tumours from patients with monoclonal plasma cell disease, and whether c-Met is activated...
  8. ncbi Osteopontin is an adhesive factor for myeloma cells and is found in increased levels in plasma from patients with multiple myeloma
    Therese Standal
    Department of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway
    Haematologica 89:174-82. 2004
    ..It is involved in a number of physiologic and pathologic events including adhesion, angiogenesis, apoptosis, inflammation, wound healing and tumor metastasis. We wanted to investigate the potential role of OPN in multiple myeloma...
  9. doi Lymphoma and myeloma cells are highly sensitive to growth arrest and apoptosis induced by artesunate
    Toril Holien
    Department of Cancer Research and Molecular Medicine, KG Jebsen Center for Myeloma Research, Norwegian University of Science and Technology, Trondheim, Norway
    Eur J Haematol 91:339-46. 2013
    ..The widely used malaria drug artesunate has been reported to have antitumor activity, and we aimed to test the effects of artesunate on a panel of myeloma and lymphoma cells...
  10. ncbi HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma
    Therese Standal
    Department of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway
    Blood 109:3024-30. 2007
    ..45, P = .008), in sera from 34 patients with myeloma. These observations suggest that HGF inhibits bone formation in multiple myeloma...
  11. ncbi Human myeloma cells adhere to fibronectin in response to hepatocyte growth factor
    Randi Utne Holt
    Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, MTFS, N 7489 Trondheim, Norway
    Haematologica 90:479-88. 2005
    ..In this work we examined the effect of hepatocyte growth factor (HGF) on the adhesion of myeloma cells and the signaling pathways involved...
  12. doi CpG-oligodeoxynucleotide inhibits Smad-dependent bone morphogenetic protein signaling: effects on myeloma cell apoptosis and in vitro osteoblastogenesis
    Nikolai N Nørgaard
    Department of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway
    J Immunol 185:3131-9. 2010
    ..In conclusion, our results demonstrate that PTO-CpG-ODN inhibits BMP-signaling, and thus might provoke unwanted TLR9-independent side effects in patients...
  13. doi FGFR3 is expressed and is important for survival in INA-6, a human myeloma cell line without a t(4;14)
    Thea K Våtsveen
    Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Olav Kyrres gt 9, N 7489 Trondheim, Norway
    Eur J Haematol 83:471-6. 2009
    ..Whether FGFR3 may play a role in MM cells without t(4;14) and the IGH-MMSET fusion protein is unclear and is the focus of this report...
  14. doi OH-2, a hyperdiploid myeloma cell line without an IGH translocation, has a complex translocation juxtaposing MYC near MAFB and the IGK locus
    Thea Kristin Våtsveen
    Department of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway
    Leuk Res 33:1670-7. 2009
    ..OH-2 provides a unique example of an HMCL and the corresponding primary tumor that are shown to share the same HRD genotype...
  15. ncbi Role of osteopontin in adhesion, migration, cell survival and bone remodeling
    Therese Standal
    Department of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway
    Exp Oncol 26:179-84. 2004
    ..In this review focus will be on OPN in bone and its role in adhesion, migration and cell survival. These aspects of OPN biology are important in tumorigenesis...
  16. ncbi Bone morphogenetic protein-5, -6 and -7 inhibit growth and induce apoptosis in human myeloma cells
    Torstein Baade Ro
    Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim N 7489, Norway
    Oncogene 23:3024-32. 2004
    ..Importantly, myeloma cells not responsive to BMP-2 and -4 may still be sensitive to BMP-6 or -7. It is possible that therapeutic use of BMP or BMP analogues could have an impact on both myeloma bone disease and myeloma cell growth...
  17. pmc Targeting proliferating cell nuclear antigen and its protein interactions induces apoptosis in multiple myeloma cells
    Rebekka Müller
    Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway
    PLoS ONE 8:e70430. 2013
    ..In a xenograft mouse model, ATX-101 was well tolerated and increased the anti-tumor activity of melphalan. Therefore, targeting PCNA by ATX-101 may be a novel strategy in multiple myeloma treatment. ..
  18. pmc Overexpression and involvement in migration by the metastasis-associated phosphatase PRL-3 in human myeloma cells
    Unn Merete Fagerli
    Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, and Department of Immunology and Transfusion Medicine, St Olavs University Hospital, Trondheim, Norway
    Blood 111:806-15. 2008
    ..In conclusion, PRL-3 is a gene product specifically expressed in malignant plasma cells and may have a role in migration of these cells...
  19. pmc Erythropoietin (EPO)-receptor signaling induces cell death of primary myeloma cells in vitro
    Thea Kristin Våtsveen
    K G Jebsen Centre of Myeloma Research, Department of Cancer Research and Molecular Medicine, Faculty of Medicine, NTNU, Norwegian University of Science and Technology, Trondheim, Norway
    J Hematol Oncol 9:75. 2016
    ..Hypoxia-dependent erythropoietin (EPO)-receptor (EPOR) signaling is central in various cancers, but the relevance of EPOR signaling in multiple myeloma cells has not yet been thoroughly investigated...
  20. doi Imatinib inhibits proliferation of human mesenchymal stem cells and promotes early but not late osteoblast differentiation in vitro
    Sofia Jonsson
    Department of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway
    J Bone Miner Metab 30:119-23. 2012
    ..This finding might partly explain why previous studies on the effects of imatinib osteoblast differentiation have shown different results...
  21. doi Association between high plasma levels of hepatocyte growth factor and progression of radiographic damage in the joints of patients with rheumatoid arthritis
    Berit Grandaunet
    Norwegian University of Science and Technology, Trondheim, Norway
    Arthritis Rheum 63:662-9. 2011
    ..The present study was thus undertaken to investigate whether plasma levels of HGF and Dkk-1 are related to bone damage in patients with rheumatoid arthritis (RA)...
  22. pmc Identification of the source of elevated hepatocyte growth factor levels in multiple myeloma patients
    Christoph Rampa
    The K, G, Jebsen Center for Myeloma Research and Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway
    Biomark Res 2:8. 2014
    ..In multiple myeloma (MM) patients it is an abundant component of the bone marrow. HGF levels are elevated in 50% of patients and associated with poor prognosis. Here we aim to investigate its source in myeloma...
  23. pmc MYC amplifications in myeloma cell lines: correlation with MYC-inhibitor efficacy
    Toril Holien
    K G Jebsen Center for Myeloma Research, Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway
    Oncotarget 6:22698-705. 2015
    ..Sensitivity of myeloma cell lines to the MYC inhibitor 10058-F4 correlated with MYC expression, supporting that the activity of 10058-F4 was through specific inhibition of MYC. ..
  24. doi Allelic mutations in noncoding genomic sequences construct novel transcription factor binding sites that promote gene overexpression
    Erming Tian
    Department of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway
    Genes Chromosomes Cancer 54:692-701. 2015
    ....
  25. ncbi Addiction to c-MYC in multiple myeloma
    Toril Holien
    KG Jebsen Center for Myeloma Research and Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway
    Blood 120:2450-3. 2012
    ..Our results provide further evidence that myeloma cells are addicted to c-MYC activity and that c-MYC is a promising therapeutic target in multiple myeloma...
  26. ncbi Serum insulinlike growth factor is not elevated in patients with multiple myeloma but is still a prognostic factor
    Therese Standal
    Institute of Cancer Research and Molecular Biology, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway
    Blood 100:3925-9. 2002
    ..In the patient group with IGF-1 levels above 13 nM, median survival was 62 months (P =.006). These findings support the hypothesis of a role for IGF-1 in myeloma disease progression...
  27. doi VOLIN and KJON-Two novel hyperdiploid myeloma cell lines
    Thea Kristin Våtsveen
    K G Jebsen Center for Myeloma Research, Department of Cancer Research and Molecular Medicine, NTNU Norwegian University of Science and Technology, Trondheim, Norway
    Genes Chromosomes Cancer 55:890-901. 2016
    ..We propose that these unique cell lines may be used as tools to increase our understanding of myeloma cell biology. © 2016 Wiley Periodicals, Inc. ..
  28. doi A method for measurement of drug sensitivity of myeloma cells co-cultured with bone marrow stromal cells
    Kristine Misund
    KG Jebsen Center for Myeloma Research and Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway
    J Biomol Screen 18:637-46. 2013
    ..Stromal cell-induced protection against common myeloma drugs is also observed with this method. ..
  29. ncbi A low serum level of soluble tumor necrosis factor receptor p55 predicts response to thalidomide in advanced multiple myeloma
    Anne Tove Brenne
    Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, MTFS, N 7489 Trondheim, Norway
    Haematologica 89:552-6. 2004
    ..Soluble TNF receptors, TNFR p55 and TNFR p75, modify TNF-alpha activity. In this study, we explored the relation between soluble TNF receptors and outcome in patients with advanced multiple myeloma treated with thalidomide...
  30. doi Soluble c-Met in serum of patients with multiple myeloma: correlation with clinical parameters
    Karin F Wader
    Department of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim
    Eur J Haematol 87:394-9. 2011
    ..We examined serum levels of soluble c-Met in patients with myeloma and healthy individuals and investigated a possible relationship with clinical disease parameters and survival...
  31. doi Hydroxychloroquine potentiates carfilzomib toxicity towards myeloma cells
    Katarzyna Baranowska
    Department of Cancer Research and Molecular Medicine, Faculty of Medicine, NTNU, Norwegian University of Science and Technology, Trondheim, Norway
    Oncotarget . 2016
    ..In conclusion, attempts should be made to combine HCQ with carfilzomib in the treatment of multiple myeloma...
  32. pmc Activin A inhibits BMP-signaling by binding ACVR2A and ACVR2B
    Oddrun Elise Olsen
    K G Jebsen Center for Myeloma Research, Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Post box 8905, MTFS, N 7491, Trondheim, Norway
    Cell Commun Signal 13:27. 2015
    ..Activin A is also elevated in myeloma patients with advanced disease and is involved in myeloma bone disease...
  33. ncbi Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells
    Therese Standal
    Institute of Cancer Research and Molecular Biology, Faculty of Medicine, Norwegian University of Science and Technology, Medisinsk Teknisk Senter, Trondheim, Norway
    Blood 100:3002-7. 2002
    ..The results suggest a novel biologic mechanism for the bone disease associated with MM and that treatment of the bone disease with OPG lacking the heparin-binding domain should be considered...
  34. pmc PDL1 Expression on Plasma and Dendritic Cells in Myeloma Bone Marrow Suggests Benefit of Targeted anti PD1-PDL1 Therapy
    Anne Marit Sponaas
    KG Jebsen Centre for Myeloma Research, Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway
    PLoS ONE 10:e0139867. 2015
    ..A correlation between the proportion of PDL1+ PC and CD141+ mDC was found, suggesting both cell types could down-regulate the anti-tumor T cell response. ..
  35. doi A-kinase anchoring protein AKAP95 is a novel regulator of ribosomal RNA synthesis
    Anne Marstad
    Centre of Molecular Inflammation Research CEMIR, Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology NTNU, Trondheim, Norway
    FEBS J 283:757-70. 2016
    ..Taken together, our data indicate that AKAP95 is a novel nucleolus-associated protein with a regulatory role on rRNA production. ..
  36. ncbi Interleukin-21 is a growth and survival factor for human myeloma cells
    Anne Tove Brenne
    Department of Cancer Research and Molecular Biology, Norwegian University of Science and Technology, Trondheim, Norway
    Blood 99:3756-62. 2002
    ..IL-21 is a novel growth and survival factor in multiple myeloma and may represent a target for future therapy...
  37. doi The role of bone morphogenetic proteins in myeloma cell survival
    Toril Holien
    KG Jebsen Center for Myeloma Research, Department of Cancer Research and Molecular Medicine, NTNU, Faculty of Medicine, Norwegian University of Science and Technology, Postbox 8905, 7491 Trondheim, Norway Electronic address
    Cytokine Growth Factor Rev 25:343-50. 2014
    ..Our review highlights and discusses the current knowledge on BMP signaling in myeloma. ..
  38. pmc Oncogene addiction to c-MYC in myeloma cells
    Toril Holien
    KG Jebsen Center for Myeloma Research and Department of Cancer Research an Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway
    Oncotarget 3:739-40. 2012
    ..c-MYC is in many cases central to cancer cell survival and due to its functional nonredundancy, it may not be easily replaced by alternative signaling mechanisms...
  39. ncbi On-pump versus off-pump coronary artery bypass grafting: more heat-shock protein 70 is released after on-pump surgery
    Brit Dybdahl
    Faculty of Medicine, Institute of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway
    Eur J Cardiothorac Surg 25:985-92. 2004
    ..Hypothesizing that use of cardiopulmonary bypass (CPB) leads to more circulating HSP70, we explored the release of it in 10 patients undergoing CABG with the use of CPB, and in 10 patients undergoing off-pump surgery CABG (OPCAB)...